Matthew Paul, MD
Ophthalmology · Danbury, CTNPI 1417955865
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $7,230 of the $10,363 with a category attached, or 69.8%. 17 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 26.8% of the total. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $154.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$3K
- Apellis Pharmaceuticals, Inc.$3K
- Eyepoint US, Inc.$2K
- Carl Zeiss Meditec USA, Inc.$1K
- Bausch & Lomb Americas Inc.$501
- Alcon$265
- plus $718 from 11 others
Across 233 payments — averaging $4017.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$603K
- Bausch Health US, LLC$163K
- Genentech, Inc.$53K
- Shire North American Group Inc$41K
- Oyster Point Pharma, Inc.$22K
- Perrigo Company PLC$19K
- plus $35K from 3 others
What the payments were for
- Speaking & faculty fees$320%
- Travel & lodging$7,23070%
- Food & beverage$3,10130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 9 | $2,774 |
| Apellis Pharmaceuticals, Inc. | 4 | $2,539 |
| Eyepoint US, Inc. | 6 | $2,163 |
| Carl Zeiss Meditec USA, Inc. | 3 | $1,405 |
| Bausch & Lomb Americas Inc. | 9 | $501 |
| Alcon | 8 | $265 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $196 |
| AbbVie | 10 | $179 |
| Rxsight Inc | 2 | $90 |
| Oyster Point Pharma, Inc. | 3 | $64 |
| Sun Pharmaceutical Industries Inc. | 2 | $42 |
| Tarsus Pharmaceuticals, Inc. | 2 | $39 |
| Lombart Brothers, Inc. | 1 | $29 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Amgen | 1 | $16 |
| ABB Con-cise Optical Group LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$2,414
- Tecnis 3-piece IOL$2,414
- Tecnis Symphony IOL$2,414
- Tecnis Symphony Toric IOL$2,414
- EYP-1901$2,146
- CIRRUS HD-OCT$1,325
- CLARUS$1,325
- FORUM$1,325
- Humphrey HFA$1,325
- IOLMaster 700$1,325
- Tecnis IOL$512
- STELLARIS$198
- CATALYS SYSTEM$150
- Voyager DSLT$149
- Hydrus Microstent$149
- ENVISTA$125
- CRYSTALENS$125
- TORIC$125
- MIEBO$125
- XIIDRA$125
How this compares
$10,363 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 70 | $100,005 |
| LumiganBimatoprost | 148 | $59,783 |
| XiidraLifitegrast | 30 | $45,184 |
| VyzultaLatanoprostene Bunod | 56 | $27,700 |
| Cyclosporine | 41 | $24,106 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,963 |
| ProlensaBromfenac Sodium | 20 | $9,527 |
| TyrvayaVarenicline Tartrate | 13 | $8,505 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $7,271 |
| Travoprost | 33 | $7,045 |
| Latanoprost | 664 | $6,930 |
| Prednisolone Acetate | 245 | $6,816 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $6,427 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 114 | $4,624 |
| Timolol Maleate | 361 | $4,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $179 | $163,184230 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $501 | $91,847111 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $196 | $9,52720 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $64 | $8,50513 claims |
| AlconSimbrinza | $265 | $7,27126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Danbury
- Mary TamDanbury$5K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
- Madina FalconeFarmington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.